|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,069 JPY | -0.49% |
|
-1.86% | +0.37% |
| Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
| Apr. 19 | Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment | MT |
Takeda Pharmaceutical Co said on Wednesday it would sell its TachoSil surgical patch product to Corza Health for 350 million euros ($414.75 million) as the Japanese company continues to divest non-core businesses.
TachoSil, a surgical patch used for bleeding control
control, delivered $160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.
To reduce debt, Takeda has pledged to dispose of $10 billion worth of non-core assets.
Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
($1 = 0.8439 euros)
(Reporting by Rocky Swift, editing by Louise Heavens)
| 1st Jan change | Capi. | |
|---|---|---|
| +0.37% | 41.31B | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 
